Search results
Results from the WOW.Com Content Network
Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. [5] It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. [2] With AS, eye and bowel problems—as well as back pain—may occur. [2]
Schober's test is a physical examination used in family medicine, physical medicine and rehabilitation, rheumatology to measure the ability of a patient to flex the lower back. Procedure [ edit ]
The Bath Ankylosing Spondylitis Functional Index was named for the location of the institution (Bath, England) where authors A. Calin and co-workers developed this validated index to determine the degree of functional limitation in patients with the inflammatory autoimmune disease Ankylosing Spondylitis (AS). These researchers recognized that ...
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).
More than 80% of patients with the ankylosing spondylitis variant test positive for the HLA-B27 biomarker, but not everyone with this biomarker will develop disease. [22] Some people with axial spondyloarthritis may test positive for elevated C-reactive protein, or CRP, depending on their disease activity. [22]
HLA-B27 is a polymorphic form of the HLA-B molecule found in up to 95% of people with ankylosing spondylitis of European ancestry, [16] [17] 70% with reactive arthritis, [18] 60% with psoriatic spondylitis, [12] 25% with peripheral psoriatic arthritis, [17] and 70% with spondylitis associated with inflammatory bowel disease.
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Pharmaceutical companies began utilizing the ASQoL to test the effectiveness of newly developed TNF inhibitors, which aid in the treatment of ankylosing spondylitis. [5] [6] Abbott has utilized the ASQoL to evaluate the impact of adalimumab [7] [8] and other organizations like Wyeth and the Medical Research Council have used it to evaluate the effect of etanercept.